Evidence-based dry-eye therapies for clinical use
8 October 2021
Volume 22, Issue 3
This article outlines a range of dry-eye disease management strategies available at each severity level and between subtypes of the disease.
Domains covered
Professionalism
Clinical practice
Specialty CPD (IP)
Despite recent advances in the management and treatment of dry-eye disease, the condition is still managed differently across continents and countries. From diagnosis to disease progression and treatment, patients should be well informed about the safe and effective use of available therapies. Consequently, this article aims to appraise eye care practitioners of a wide range of management strategies available at each severity level and between subtypes of dry-eye disease.
Sign in to view the article
Not a member? Start enjoying the benefits of College membership today. Take a look at what the College can offer you and view our membership categories and rates.
Related further reading
Adrian O’Dowd examines why optometrists need to act on behalf of patients who report temporary sight loss in one eye caused by amaurosis fugax, a potentially serious and sometimes overlooked condition.
Evidence suggests that obstructive sleep apnoea increases the risk of normal-tension glaucoma writes Kim Thomas, but is there a causal mechanism?
This online peer review session is open to College members and will cover your GOC peer review requirement.